Loomis, Sayles & Company
COLL icon

Loomis, Sayles & Company’s Collegium Pharmaceutical COLL Stock Holding History

Loomis, Sayles & Company’s Portfolio COLL Stock Details COLL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.2M Sell
364,999
-10,667
-3% -$365K 0.02% 337
2026
Q1 		$12.4M Buy
375,666
+43,097
+13% +$1.82M 0.02% 318
2025
Q4 		$15.4M Buy
332,569
+14,689
+5% +$615K 0.02% 284
2025
Q3 		$11.1M Sell
317,880
-19,257
-6% -$669K 0.01% 338
2025
Q2 		$9.97M Buy
337,137
+149,766
+80% +$4.27M 0.01% 381
2025
Q1 		$5.59M Buy
187,371
+187,262
+171,800% +$5.72M 0.01% 414
2024
Q4 		$3K Sell
109
-18,966
-99% -$628K ﹤0.01% 715
2024
Q3 		$737K Sell
19,075
-182,234
-91% -$6.5M ﹤0.01% 467
2024
Q2 		$6.48M Sell
201,309
-70,643
-26% -$2.45M 0.01% 406
2024
Q1 		$10.6M Sell
271,952
-4,177
-2% -$146K 0.02% 349
2023
Q4 		$8.5M Buy
276,129
+2,501
+0.9% +$62.6K 0.01% 352
2023
Q3 		$6.12M Buy
273,628
+67,439
+33% +$1.54M 0.01% 378
2023
Q2 		$4.43M Buy
+206,189
New +$4.68M 0.01% 403

Other funds holding COLL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Loomis, Sayles & Company's COLL Position: Q2 2026 in Review

Loomis, Sayles & Company reduced its Collegium Pharmaceutical (COLL) stake by 2.8% in Q2 2026, selling an estimated $365K and leaving 364,999 shares worth $13.2M. The position accounts for 0.02% of the portfolio, ranked #337.

Loomis, Sayles & Company first reported a position in COLL in Q2 2023 and has held it in 13 quarters since. The position peaked at $15.4M in Q4 2025. 279 funds tracked by Wall St. Rank hold COLL as of Q2 2026.

  • Loomis, Sayles & Company held 364,999 shares of Collegium Pharmaceutical worth $13.2M as of Q2 2026.
  • Loomis, Sayles & Company sold 10,667 Collegium Pharmaceutical shares in Q2 2026, an estimated $365K.
  • Collegium Pharmaceutical made up 0.02% of Loomis, Sayles & Company's portfolio in Q2 2026, its #337 holding.
  • Loomis, Sayles & Company first reported a position in Collegium Pharmaceutical in Q2 2023 and has held it in 13 quarters since.
  • Loomis, Sayles & Company's Collegium Pharmaceutical position peaked at $15.4M in Q4 2025.
  • 279 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q2 2026.

Based on Loomis, Sayles & Company's 13F filing for Q2 2026, filed 14 Aug 2026.